Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07429266 · ClinicalTrials.gov registry record · Phase 3
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
A Phase 3 study, sponsored by Ono Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT07429266: Recruiting Phase 3 study, sponsored by Ono Pharmaceutical Co..
NCT07429266 is a Phase 3 study that is actively recruiting participants, run by Ono Pharmaceutical Co.. The registered enrollment target is 250 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07429266, a Phase 3 study, is actively recruiting participants, sponsored by Ono Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
Primary Outcome
Response is defined as absence of phlebotomy eligibility.
Interventions
- DRUG Placebo
- DRUG Sapablursen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-05-25 |
| Est. Completion | 2031-01 |
| Phase | Phase 3 |
What NCT07429266 shows while recruiting
NCT07429266 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07429266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07429266 about?
NCT07429266 is a clinical study titled "INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)". The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term exte...
What is the current status of trial NCT07429266?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2026-05-25. Estimated completion is 2031-01.
What interventions are being tested in trial NCT07429266?
The interventions under investigation include: Placebo (DRUG), Sapablursen (DRUG).
Who is sponsoring clinical trial NCT07429266?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07429266's enrollment target sits among peer trials
250 1249th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI